This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.
Bristol-Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well.
Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
by Kinjel Shah
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Bristol-Myers' (BMY) Q1 Earnings & Sales Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the first quarter on strong performance of Revlimid and Eliquis.
Jobless Claims on Downward Slope to 3.169M Last Week
by Mark Vickery
New initial claims registered 3.169 million, above the 3.10 million expected by analysts but beneath the previous week's 3.84 million.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Bristol-Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol-Myers (BMY) delivered earnings and revenue surprises of 16.22% and 8.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.
Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Powerful Proof Anyone Can Invest for an Early Retirement - May 05, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while its revenues too beat estimates.
Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.
This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
How Trading Your Own Retirement Can Fleece Your Financial Future - May 01, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Bristol-Myers Squibb (BMY) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $61.11, marking a -0.84% move from the previous day.
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Strategic Education, Lockheed Martin, Bristol-Myers Squibb, Dollar General and The Kroger
by Zacks Equity Research
Zacks.com featured highlights include: Strategic Education, Lockheed Martin, Bristol-Myers Squibb, Dollar General and The Kroger
Forget Dividend Cuts, Here Are 5 Solid Growth Picks for You
by Sweta Killa
Against the backdrop of near-zero interest environment and a series of drastic dividend cuts, investors are zeroing in on stocks that not only offer dividends but also consistently increase their payout.